EMA Withdrawn: Victrelis (Boceprevir) — Merck Sharp Dohme Ltd

View source ↗

Summary

EMA has withdrawn Victrelis (boceprevir) from the market in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Victrelis (boceprevir)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis C, Chronic. MAH: Merck Sharp Dohme Ltd. Decision date: 29/06/2017